Amendments to the Claims:

The following listing of claims will replace all prior versions and listings of the claims in this application.

Listing of Claims:

1 (previously presented). A pharmaceutical composition comprising an effective amount of amlodipine maleate and at least one pharmaceutically acceptable excipient wherein said composition has a pH within the range of 5.5 - 6.8 and is in solid form.

2 (previously presented). The composition according to claim 1, wherein said composition has a pH of about 6.0 - 6.8.

3 (cancelled).

4 (original). The composition according to claim 1, wherein said excipient is calcium phosphate or microcrystalline cellulose.

5 (original). The composition according to claim 4, wherein said composition comprises calcium phosphate and microcrystalline cellulose.

6 (original). The composition according to claim 4, wherein said excipient is calcium hydrogen phosphate.

7 (original). The composition according to claim 4, wherein said excipient is microcrystalline cellulose.

8 (original). The composition according to claim 1, wherein said composition further comprises an acidic pH adjusting agent.

9 (original). The composition according to claim 1, wherein said composition is in the form of a tablet.

10 (original). The composition according to claim 9, which further comprises an outer layer surrounding said tablet.

11 (original). The composition according to claim 1, wherein said composition is in the form of a capsule.

12 (original). The composition according to claim 1, wherein said amount of amlodipine maleate corresponds to 1.0 to 25 mg of amlodipine free base.

13 (original). The composition according to claim 12, wherein said amount of amlodipine maleate corresponds to 1.25, 2.5, 5 or 10 mg of amlodipine free base.

14 (original). A method for treating or preventing angina, hypertension, or heart failure, which comprises administering to a patient in need thereof an effective amount of the composition according to claim 1.

15 (previously presented). A process for making the composition according to claim 1, which comprises mixing amlodipine maleate and at least one pharmaceutically acceptable excipient to form a mixture having a pH within the range of 5.5 to 6.8.

16 (previously presented). A process, which comprises:

mixing amlodipine maleate and at least one pharmaceutically acceptable excipient to form a mixture having a pH of 5.5-6.8.

17 (original). The process according to claim 16, which further comprises compressing said mixture into a tablet.

18 (original). The process according to claim 16, which further comprises filling capsules with said mixture to form a pharmaceutical dosage form.

19 (original). The process according to claim 16, wherein said mixing is carried out by wet granulation.

20 (original). The process according to claim 16, wherein said mixing is carried out by a dry method.

21 (original). The process according to claim 20, wherein said amlodipine maleate is mixed as solid particles having an average particle size of at least 100 microns with said excipient.

22 (original). A tablet made according to the process of claim 16.

23-27 (cancelled).

28 (previously presented). The composition according to claim 8, wherein said pH adjusting agent is a pharmaceutically acceptable acid.

29 (previously presented). The composition according to claim 28, wherein said pharmaceutically acceptable acid is maleic acid, citric acid, or ascorbic acid.

30 (previously presented). The composition according to claim 29, wherein said pharmaceutically acceptable acid is maleic acid.

31 (previously presented). The composition according to claim 1, wherein said composition comprises an acidic excipient.

32 (previously presented). The composition according to claim 1, wherein said amlodipine maleate has an average particle size of at least 20 microns.

33 (previously presented). The composition according to claim 32, wherein said amlodipine maleate has an average particle size of at least 100 microns.

34-36 (not entered).

37 (new). The composition according to claim 1, wherein said composition has a pH within the range of about 5.5-6.2.

38 (new). The composition according to claim 1, wherein said composition has a pH within the range of about 6.0-6.2.

39 (new). The composition according to claim 9, wherein said composition has a pH within the range of about 5.5-6.2.

40 (new). The composition according to claim 1, wherein said excipient is pH inert.

41 (new). The composition according to claim 40, wherein said excipient is microcrystalline cellulose.

42 (new). The composition according to claim 1, wherein at least one excipient is an acidic excipient.

43 (new). The composition according to claim 42, wherein said acidic excipient is a sodium starch glycolate.

44 (new). The composition according to claim 43, which further comprises microcrystalline cellulose.

45 (new). The composition according to claim 44, wherein the sum of excipients other than said microcrystalline cellulose is less than 10 wt% based on the total weight of the composition.

46 (new). The composition according to claim 43, which further comprises a calcium phosphate.

47 (new). The composition according to claim 46, wherein the sum of excipients other than said calcium phosphate is less than 10 wt% based on the total weight of the composition.